2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2596

Comparable Safety and Immunogenicity and Sustained Efficacy after Transition to SB2 (An Infliximab Biosimilar) Vs Ongoing Reference Infliximab (Remicade®) in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2809

Comparative Analysis of Anti-Nuclear Antibody Testing Using Blinded Replicate Samples Reveals Variability Between Commercial Testing Laboratories

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2529

Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2746

Comparing Prevalence of Comorbidities in Patients with Psoriatic Arthritis By Biologic Therapy

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2242

Comparison of Assessment and Management of RA and Other Rheumatic Diseases By Rheumatologists in Private Practices or an Academic Medical Center

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2803

Comparison of Clinical and Serological Differences According to the Autoantibody Cluster in Women with Systemic Lupus Erythematosus: Results from the Korean Lupus Network (KORNET) Registry

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2333

Comparison of Clinical Outcomes of Total Ankle Arthroplasty Between Biologics and NON-Biologics Treatment Groups in Patients with Rheumatoid Arthritis

Orthopedics, Low Back Pain and Rehabilitation - Poster

9:00AM-11:00AM: Abstract Number: 2755

Comparison of Clinical Profile of Geriatric and Non-Geriatric Ankylosing Spondylitis (AS) Patients

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2249

Comparison of Discontinuation Rates Among Patients with RA Initiating Biologics

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2464

Comparison of Disease Activity Score (DAS) 28-CRP to DAS28-ESR in Patients with Active Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2586

Comparison of Intra-Articular Methylprednisolone Acetate with Triamcinolone Acetonide in Acutely Swollen Knee Joint of Patients with Chronic Inflammatory Arthritis – a Randomized Controlled Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2538

Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2815

Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2202

Comparison of New and Old American College of Rheumatology Classification Criterion for Diagnosis of Fibromyalgia

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

9:00AM-11:00AM: Abstract Number: 2197

Comparison of Objectively Measured Physical Activity Among People with Symptomatic Knee Osteoarthritis with the General US Population

Epidemiology and Public Health - ARHP Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].